References
- Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a
clinician’s guide to terminology, documentation, and reporting.Ann Intern Med 2004;140:795–801.
- Rosoff PM. The two-edged sword of curing childhood cancer. N
Engl J Med 2006;355:1522–3.
- Agarwal S, Classen D, Larsen G, et al. Prevalence of adverse events in
pediatric ICUs in the United States. Pediatr Crit Care Med2010;11:568–78.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions
in hospitalized patients: a meta-analysis of prospective studies.JAMA 1998;279:1200–5.
- Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as
cause of admission to hospital: prospective analysis of 18820
patients. BMJ 2004;329: 15-19.
- White TJ, Arakelian A, Rho JP. Counting the costs of drug-related
adverse events. Pharmacoeconomics 1999;15:445–58.
- Carleton BC, Smith MA. Drug safety: Side effects and mistakes or
adverse reactions and deadly errors? BCMJ 2006;48:329-33.
- Hazell L, Shakir SAW. Under-reporting of adverse drug reactions.Drug Safety 2006;29: 385-96.
- Hoppu K. Paediatric clinical pharmacology: at the beginning of a new
era. Eur J Clin Pharmacol 2008;64:201–5.
- Bonati M, Choonara I, Hoppu K, et al. Closing the gap in drug therapy.Lancet 1999;353:1625.
- Pandolfini C, Bonati M. A literature review on off-label drug use in
children. Eur J Pediatr 2005;164:552–8.
- Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse
drug reactions in paediatric in/out-patients: a systemic review and
meta-analysis of prospective studies. Br J Clin Pharmacol2001;52: 77-83.
- Khaled LA, Ahmad F, Brogan T, et al. Prescription drug use by one
million Canadian children. Paediatr Child Health 2003;8(Suppl
A):6A–56A.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the
probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
- Macedo AF, Marques FB, Ribeiro CF, et al. Causality assessment of
adverse drug reactions: comparison of the results obtained from
published decisional algorithms and from the evaluations of an expert
panel. Pharmacoepidemiol Drug Saf 2005;14:885–90.
- Avner M, Finkelstein Y, Hackam D, Koren G. Establishing causality in
pediatric adverse drug reactions: use of the Naranjo probability
scale. Paediatr Drugs 2007;9:267–70.
- Kane-Gill SL.Are the Naranjo criteria reliable and valid for
determination of adverse drug reactions in the intensive care unit?Annals Of Pharmacotherapy 2005;39:1823–7.
- Garcia-Cortes M, Lucena MI, Pachkoria K, et al. Evaluation of Naranjo
Adverse Drug Reactions Probability Scale in causality assessment of
drug-induced liver injury. Aliment Pharmacol Ther2008;27:780–9.
- Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater
reliability of the Liverpool adverse drug reaction causality
assessment tool. PLoS One 2011;6:e28096.
- Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity.BMJ 1994;308(6943):1552.
- Altman DG, Bland JM. Diagnostic tests 2: predictive
values. BMJ 1994;309(6947):102.
- Wong T, Atkinson A, t’Jong G, Rieder MJ. Beta-lactam in the paediatric
population. Paediatr Child Health 2020;25:762-3.
- Line J, Thomson P, Naisbitt DJ. Pathology of T-cel mediated drug
hypersensitivity reactions and impact of tolerance mechanisms on
patient susceptibility. Curr Opin Allergy Clin Immunol
2022;22:226-233.
- Elzagallaai AA, Rieder MJ. Model based evaluation of hypersensitivity
adverse drug reactions for antimicrobial agents in children. Front
Pharmacol 2021 30;12:63888..
- Elzagallaai AA, Koren G, Rieder MJ. The predictive value of the in
vitro platelet toxicity assay (iPTA) for the diagnosis of
hypersensitivity reactions to sulfonamides. J Clin Pharmacol.
2013;53(6):626-32.